| Bioactivity | CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer[1]. |
| Target | Kd for CD137: 50 nM (human); 61 nM (cynomolgus macaque); 748 nM (mouse) |
| Invitro | CTX-471 (5-500 nM) has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively[1].CTX-471 binds to a unique epitope on CD137[1].CTX-471 (0.1-100 nM; 1, 10 μg/mL; 3 days) increases IFN-y production by human T cells in an Fcy receptor-dependent (FcyR-dependent) manner in vitro[1]. |
| In Vivo | CTX-471 (i.p.; 150 μg) exhibits curative monotherapy activity in various syngeneic tumor models and shows a unique ability to cure mice of very large tumors.CTX-471 (i.v.; 10-80 mg/kg; on days 0, 7, 14, and 21) is well tolerated, with no signs of hepatic toxicity in high doses. Animal Model: |
| Name | CTX-471 |
| CAS | 2377152-49-1 |
| Formula | CT |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ugur Eskiocak, et al. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020 Mar 12;5(5):e133647. |